Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if mirvetuximab soravtansine can help
to control either newly diagnosed or metastatic (has spread) triple-negative breast cancer
(TNBC).
Mirvetuximab soravtansine is designed to stop cell growth by blocking certain proteins in
the cancer cells related to the mineral folate. This is believed to cause the cancer cells
to die.